As researchers push for a type 1 diabetes cure, Sana Biotechnology has provided a nudge forward with new, if limited, ...
Hosted on MSN16d
This Biotech Penny Stock Is Up 120% This Year. Analysts Think It Can Still Triple From Here in 2025.Sana Biotechnology (SANA), a clinical-stage ... modified islet cells were able to evade immune system attacks. CEO Steve Harr stated, “As far as we are aware, this is the first study showing ...
Shares of Sana Biotechnology surged after the company ... intramuscularly with no immunosuppression," Chief Executive Steve Harr said.
SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology ... will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will ...
and evasion of immune detection of HIP-modified primary pancreatic islet cells transplanted intramuscularly with no immunosuppression,” said Steve Harr, Sana's President and Chief Executive ...
Sana Biotechnology’s hypoimmune platform enables it to make a series of genetic modifications to cells, rendering the cells ...
Detailed price information for Sana Biotechnology Inc (SANA-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback